Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc., shared on X:
“Phase 1b of Iza-Bren in patients with ES-SCLC published on Journal of Clinical Oncology!
Iza-Bren designed to simultaneously engage both EGFR and HER3 (high affinity for EGFR, low affinity for HER3), topo1 payload Interesting discussion on the correlation between EGFR/HER3 expression and activity.
Caveat: small sample size.
In previous biomarker analysis of Iza-bren in ESCC, no relationship was noticed between EGFR or HER3 expression and antitumor responses.”
Title: Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study
Authors: Yuanyuan Zhao, Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang, Yan Huang
Read the full article.
Discover more:
Izalontamab Brengitecan Shows Encouraging Activity in Relapsed ES-SCLC
